Natera Responds to Meritless Lawsuit and Files False Adverti

Natera Responds to Meritless Lawsuit and Files False Advertising Claim Against Guardant for Misleading Oncologists
News provided by
Share this article
Share this article
AUSTIN, Texas, May 28, 2021 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA (cfDNA) testing, today announced it has been sued by Guardant Health, in an attempt to stop Natera from exposing Guardant Reveal's™ true test performance and the differences between tumor-informed and tumor-naive molecular residual disease (MRD) tests.
Natera has filed a claim against Guardant in the U.S. District Court for the Western District of Texas, (Docket No.6:21-cv-00540), alleging that Guardant used false and misleading claims to deceive physicians about the performance capabilities of its MRD test, in violation of the Lanham Act. Guardant's MRD test performance claims are incomplete or unsupported by clinical evidence, and can be misinterpreted by physicians and patients. 

Related Keywords

California , United States , Texas , San Carlos , Mike Brophy , Kate Stabrawa , Natera Inc , Guardant Health , Clinical Laboratory Improvement Amendments , Us District Court , Nasdaq , Clinical Cancer Research , Guardant Reveal , Western District , Healthcare Conference , Residual Disease Detection , Plasma Only Circulating Tumor , Colorectal Cancer , Clinical Cancer , Natera , Nc , கலிஃபோர்னியா , ஒன்றுபட்டது மாநிலங்களில் , டெக்சாஸ் , சான் கார்லோஸ் , மைக் கோப்பை , மருத்துவ ஆய்வகம் முன்னேற்றம் திருத்தங்கள் , எங்களுக்கு மாவட்டம் நீதிமன்றம் , நாஸ்டாக் , மருத்துவ புற்றுநோய் ஆராய்ச்சி , மேற்கு மாவட்டம் , சுகாதாரம் மாநாடு , பெருங்குடல் புற்றுநோய் , மருத்துவ புற்றுநோய் , ந்ஸீ ,